Edition:
United Kingdom

People: Amarin Corporation PLC (AMRN.OQ)

AMRN.OQ on NASDAQ Stock Exchange Global Market

17.33USD
8:59pm GMT
Change (% chg)

$-0.82 (-4.52%)
Prev Close
$18.15
Open
$17.82
Day's High
$18.13
Day's Low
$16.75
Volume
1,605,665
Avg. Vol
2,436,793
52-wk High
$23.33
52-wk Low
$2.36

Ketchum, Stephen 

Dr. Stephen B. Ketchum, Ph.D., is President - Research and Development, Senior Vice President, Chief Scientific Officer of Amarin Corp Plc. Dr. Ketchum has a significant record of achievement in the life sciences industry, with 20 years of experience in late-stage product development and clinical regulatory strategy, having led the filings of multiple successful new drug applications (NDAs) and supplemental NDAs. Prior to joining Amarin, Dr. Ketchum served as senior vice president, research and development for Sunesis Pharmaceuticals where, as a member of the Executive Committee, he provided strategic direction for all facets of research and development, including clinical strategy and operations, regulatory affairs, and pharmaceutical development. Prior to Sunesis, Dr. Ketchum was senior vice president, research and development and medical affairs at Reliant Pharmaceuticals with responsibilities for leading the strategic direction and day-to-day operations of Reliant's clinical research, product development, and medical affairs departments, including responsibilities for Lovaza, an earlier generation prescription omega-3 drug. Dr. Ketchum has also served as senior vice president, operations and regulatory affairs for IntraBiotics Pharmaceuticals, Inc., where he was responsible for regulatory affairs, project management, quality assurance, and supply chain management in support of late-stage clinical research.

Basic Compensation

Total Annual Compensation, USD 523,342
Restricted Stock Award, USD 345,780
Long-Term Incentive Plans, USD --
All Other, USD 329,468
Fiscal Year Total, USD 1,198,590

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lars Ekman

--

John Thero

2,769,490

Michael Kalb

--

Stephen Ketchum

1,198,590

Joseph Kennedy

1,201,640

Aaron Berg

--
As Of  31 Dec 2014